Pulmatrix, Inc. (PULM)
1.55
+0.16
(+11.11%)
USD |
NASDAQ |
Sep 09, 14:00
Pulmatrix Enterprise Value : 3.193M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 3.193M |
| September 04, 2026 | 3.175M |
| September 03, 2026 | 3.065M |
| September 02, 2026 | 3.467M |
| September 01, 2026 | 3.668M |
| August 31, 2026 | 3.467M |
| August 28, 2026 | 3.613M |
| August 27, 2026 | 3.650M |
| August 26, 2026 | 3.668M |
| August 25, 2026 | 3.942M |
| August 24, 2026 | 3.759M |
| August 21, 2026 | 3.558M |
| August 20, 2026 | 3.576M |
| August 19, 2026 | 3.650M |
| August 18, 2026 | 3.759M |
| August 17, 2026 | 3.796M |
| August 14, 2026 | 3.722M |
| August 13, 2026 | 3.613M |
| August 12, 2026 | 3.942M |
| August 11, 2026 | 3.942M |
| August 10, 2026 | 3.832M |
| August 07, 2026 | 4.161M |
| August 06, 2026 | 4.161M |
| August 05, 2026 | 4.124M |
| August 04, 2026 | 4.161M |
| Date | Value |
|---|---|
| August 03, 2026 | 4.453M |
| July 31, 2026 | 4.453M |
| July 30, 2026 | 4.307M |
| July 29, 2026 | 4.197M |
| July 28, 2026 | 4.234M |
| July 27, 2026 | 4.416M |
| July 24, 2026 | 4.124M |
| July 23, 2026 | 4.563M |
| July 22, 2026 | 4.270M |
| July 21, 2026 | 4.307M |
| July 20, 2026 | 4.234M |
| July 17, 2026 | 4.270M |
| July 16, 2026 | 3.978M |
| July 15, 2026 | 3.832M |
| July 14, 2026 | 4.015M |
| July 13, 2026 | 4.197M |
| July 10, 2026 | 4.38M |
| July 09, 2026 | 4.672M |
| July 08, 2026 | 4.964M |
| July 07, 2026 | 4.416M |
| July 06, 2026 | 4.416M |
| July 02, 2026 | 4.38M |
| July 01, 2026 | 4.453M |
| June 30, 2026 | 4.307M |
| June 29, 2026 | 2.879M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.848B |
| Corcept Therapeutics, Inc. | 12.00B |
| Veru, Inc. | 20.88M |
| Johnson & Johnson | 676.38B |
| Eli Lilly & Co. | 1.104T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.036M |
| Total Expenses (Quarterly) | 1.036M |
| EPS Diluted (Quarterly) | -0.288 |
| Earnings Yield | -71.17% |
| Normalized Earnings Yield | -71.17 |